Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02769520 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
A Phase 2 study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Assuntina G. Sacco, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 3
- Study locations
NCT02769520: Active Phase 2 study of Squamous Cell Carcinoma of the Head and Neck, sponsored by Assuntina G. Sacco, MD.
NCT02769520 is a Phase 2 study of Squamous Cell Carcinoma of the Head and Neck that is active but no longer recruiting, run by Assuntina G. Sacco, MD. The registered enrollment target is 27 participants, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02769520, a Phase 2 study of Squamous Cell Carcinoma of the Head and Neck, is active but no longer recruiting, sponsored by Assuntina G. Sacco, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following locoregional disease recurrence.
Primary Outcome
Disease-Free Survival
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (3)
California
- UCSD Moores Cancer Center - La Jolla
- University of California San Francisco - San Francisco
- University of California Los Angeles - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-07-06 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT02769520 still lists
NCT02769520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 145-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02769520 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02769520 about?
NCT02769520 is a clinical study titled "Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck". The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following locoregional disease recurrence.
What is the current status of trial NCT02769520?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2016-07-06. Estimated completion is 2026-04.
What conditions does trial NCT02769520 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Head and Neck.
What interventions are being tested in trial NCT02769520?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02769520?
This trial is sponsored by Assuntina G. Sacco, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02769520 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02769520's enrollment target sits among peer trials
27 25th of 29 higher than 5 of 29 other Squamous Cell Carcinoma of the Head and Neck trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of the Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
RECRUITING · Phase 2
-
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
ACTIVE NOT RECRUITING · Phase 2
-
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
ACTIVE NOT RECRUITING · Phase 2
-
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI